286 related articles for article (PubMed ID: 27444983)
21. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
[TBL] [Abstract][Full Text] [Related]
22. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
23. St John's wort and depression: slight efficacy at best, many drug interactions.
Prescrire Int; 2004 Oct; 13(73):187-92. PubMed ID: 15499702
[TBL] [Abstract][Full Text] [Related]
24. Advantages and Disadvantages of Using St. John's Wort as a Treatment for Depression.
Canenguez Benitez JS; Hernandez TE; Sundararajan R; Sarwar S; Arriaga AJ; Khan AT; Matayoshi A; Quintanilla HA; Kochhar H; Alam M; Mago A; Hans A; Benitez GA
Cureus; 2022 Sep; 14(9):e29468. PubMed ID: 36299970
[TBL] [Abstract][Full Text] [Related]
25. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.
Will-Shahab L; Bauer S; Kunter U; Roots I; Brattström A
Eur J Clin Pharmacol; 2009 Mar; 65(3):287-94. PubMed ID: 19015839
[TBL] [Abstract][Full Text] [Related]
26. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.
Whitten DL; Myers SP; Hawrelak JA; Wohlmuth H
Br J Clin Pharmacol; 2006 Nov; 62(5):512-26. PubMed ID: 17010103
[TBL] [Abstract][Full Text] [Related]
27. Clinically relevant safety issues associated with St. John's wort product labels.
Clauson KA; Santamarina ML; Rutledge JC
BMC Complement Altern Med; 2008 Jul; 8():42. PubMed ID: 18637192
[TBL] [Abstract][Full Text] [Related]
28. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.
Henderson L; Yue QY; Bergquist C; Gerden B; Arlett P
Br J Clin Pharmacol; 2002 Oct; 54(4):349-56. PubMed ID: 12392581
[TBL] [Abstract][Full Text] [Related]
29. Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho YF; Huang DK; Hsueh WC; Lai MY; Yu HY; Tsai TH
Life Sci; 2009 Aug; 85(7-8):296-302. PubMed ID: 19559714
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of St. John's wort drug interactions revisited.
Nicolussi S; Drewe J; Butterweck V; Meyer Zu Schwabedissen HE
Br J Pharmacol; 2020 Mar; 177(6):1212-1226. PubMed ID: 31742659
[TBL] [Abstract][Full Text] [Related]
31. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
[TBL] [Abstract][Full Text] [Related]
32. Effect of St. John's Wort standardized extract and hypericin on in vitro placental calcium transport.
da Conceição AO; Takser L; Lafond J
J Med Food; 2010 Aug; 13(4):934-42. PubMed ID: 20553141
[TBL] [Abstract][Full Text] [Related]
33. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
34. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
35. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S
Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201
[TBL] [Abstract][Full Text] [Related]
36. Safety of hormonal contraceptives among women with migraine: A systematic review.
Tepper NK; Whiteman MK; Zapata LB; Marchbanks PA; Curtis KM
Contraception; 2016 Dec; 94(6):630-640. PubMed ID: 27153744
[TBL] [Abstract][Full Text] [Related]
37. 'Less like a drug than a drug': the use of St John's wort among people who self-identify as having depression and/or anxiety symptoms.
Pirotta M; Willis K; Carter M; Forsdike K; Newton D; Gunn J
Complement Ther Med; 2014 Oct; 22(5):870-6. PubMed ID: 25440378
[TBL] [Abstract][Full Text] [Related]
38. St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study.
Shibayama Y; Ikeda R; Motoya T; Yamada K
Food Chem Toxicol; 2004 Jun; 42(6):995-1002. PubMed ID: 15110109
[TBL] [Abstract][Full Text] [Related]
39. St. John's wort and oral contraceptives: reasons for concern?
Murphy PA
J Midwifery Womens Health; 2002; 47(6):447-50. PubMed ID: 12484666
[TBL] [Abstract][Full Text] [Related]
40. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
Arold G; Donath F; Maurer A; Diefenbach K; Bauer S; Henneicke-von Zepelin HH; Friede M; Roots I
Planta Med; 2005 Apr; 71(4):331-7. PubMed ID: 15856409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
